Vosoritide (VOXZOGO): Uses, Mechanism, and Evidence

Parents of children with achondroplasia often want to know whether a therapy can influence bone growth during the years that growth plates remain open. Vosoritide is one of the few options developed specifically for this question, and its approval rests on a defined growth-velocity measure rather than a broader outcome.

Key takeaways

• Vosoritide is marketed as VOXZOGO and is a C-type natriuretic peptide (CNP) analog.
• It is approved to increase linear growth in pediatric patients with achondroplasia who still have open epiphyses.
• The approval is an accelerated approval based on annualized growth velocity, pending confirmatory trial data.
• Vosoritide's label does not carry a boxed warning.
• At least 18 trials have studied vosoritide, including work in related skeletal growth conditions.

What Vosoritide Is

Vosoritide is a synthetic analog of C-type natriuretic peptide (CNP), a signaling molecule involved in bone growth. In achondroplasia, a mutation in the FGFR3 receptor overactivates a pathway (through ERK1/2 signaling) that suppresses bone growth at the growth plate. Vosoritide binds to a receptor called NPR-B and works to counteract that overactive signaling, which is thought to support more typical growth plate activity. It is identified in chemical databases under PubChem CID 119058036.

What Vosoritide Is Approved For

VOXZOGO is approved to increase linear growth in pediatric patients with achondroplasia who have open epiphyses, meaning their growth plates have not yet closed. The approval was granted on an accelerated basis, reflecting demonstrated improvement in annualized growth velocity rather than a long-term functional outcome. Continued approval for this indication may depend on results from confirmatory trials. It is marketed under the brand name VOXZOGO in multiple dose strengths. The label does not include a boxed warning.

What the Evidence Shows

Vosoritide has been studied in at least 18 registered clinical trials. Beyond its approved use in achondroplasia, ongoing research includes a Phase 1/2 trial examining safety and efficacy for growth deficits in MPS IVA and VI, currently active but not recruiting. A Phase 3 long-term extension study is also enrolling by invitation to evaluate vosoritide in children with hypochondroplasia, a related skeletal growth condition. A separate Phase 2 trial has examined vosoritide's safety in at-risk infants with achondroplasia.

Reported Side Effects

Reports submitted to the FDA Adverse Event Reporting System for vosoritide have centered on medication handling issues, including dose calculation errors, product preparation errors, and product prescribing errors, each recorded a small number of times. These figures represent counts of submitted reports, not confirmed rates of incidence or proof that vosoritide caused the event.